tofacitinib
tofacitinib: developed by 1 company · 6 clinical trials tracked · 2 FDA decisions.
tofacitinib evidence translation
What we can confirm
2 FDA records · 6 tracked trials
What it means
What to watch
Prepared research question
How could tofacitinib → PFE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 3 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| PFIZER INC (PFE) Psoriatic Arthritis, Juvenile | Approved |
| PFIZER INC (PFE) Psoriatic Arthritis, Juvenile | Approved |
Clinical Trials (6)
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Primary endpoint: Number of participants with MiDA
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Disease Phase IIa Open-Label Clinical Trial and Associated Mechanistic Studies
Primary endpoint: Number of Adverse Events by Grade/Category
An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Primary endpoint: Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo Score
KOREAN POST-MARKETING SURVEILLANCE FOR XELJANZ® 5 MG FILM-COATED TABLETS AND XELJANZ® 1 MG/ML ORAL SOLUTION IN PATIENTS WITH ACTIVE PJIA AND JPSA
Primary endpoint: Number of patients with treatment emergent treatment-related adverse events
Tofacitinib: Suppressing Tumor Invasion in Recurrent GBM Patients
Primary endpoint: Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.
OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Primary endpoint: Remission by central read Mayo score following 44 weeks in the maintenance phase.
FDA Decisions2 records
Frequently asked questions
Who is developing tofacitinib?
tofacitinib is being developed by PFIZER INC.
How many clinical trials involve tofacitinib?
BioSniper tracks 6 clinical trials involving tofacitinib.
What is tofacitinib's latest FDA decision?
The most recent tracked FDA decision for tofacitinib is Approval for 1 INDICATIONS AND USAGE XELJANZ (tablets and oral solution) and XELJANZ XR (extended-release tablets) are Janus kinase (JAK) inhibitors. XELJANZ tablets and XELJANZ XR are indicated for the treatment of adult patients with: • Moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers. • Active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. • Active ankylosing s, dated September 25, 2020.